Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 04/24 04:29:17 pm
159.79 USD   -0.06%
09:54aBIOCENTURY - MA : Probiodrug, Alder
AQ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE..
DJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about ALLERGAN PLC
09:54aBIOCENTURY - MANAGEMENT TRACKS : Probiodrug, Alder
AQ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20ALLERGAN : Showcases Leadership in Neurosciences with 25 Presentations at the Am..
PU
04/20Shire rejects third Takeda bid, Allergan mulling offer
AQ
04/20Shire rejects third Takeda bid, as Allergan drops out
AQ
04/20Shire Attracts Flurry Of Suitors -- WSJ
DJ
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19ALLERGAN : Does Not Intend to Make an Offer for Shire plc; Strategic Review Cont..
PR
04/19EUROPE MARKETS : European Stocks Edge Up As Deal Developments, Earnings Reports ..
DJ
04/19EXCLUSIVE - ALLERGAN IN TALKS TO ACQ : sources
RE
04/19ALLERGAN : Issues Statement Regarding Press Speculation on its Strategic Review
PR
04/19ALLERGAN : Statement Regarding Strategic Review
DJ
More most relevant news
All news about ALLERGAN PLC
09:54aBIOCENTURY - MANAGEMENT TRACKS : Probiodrug, Alder
AQ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20ALLERGAN : Showcases Leadership in Neurosciences with 25 Presentations at the Am..
PU
04/20Shire rejects third Takeda bid, Allergan mulling offer
AQ
04/20Shire rejects third Takeda bid, as Allergan drops out
AQ
04/20Shire Attracts Flurry Of Suitors -- WSJ
DJ
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
More news
Sector news : Pharmaceuticals - NEC
03:32pTAKEDA PHARMACEUTICAL : Statement -2-
DJ
03:32pTakeda Pharmaceutical Company Ltd Statement Regarding Shire plc
DJ
02:45pShire receives new bid from Takeda as takeover deadline looms
RE
02:33pASTRAZENECA : raises stake in respiratory partner Circassia
RE
02:25pINVESCO UK LTD INVESCO LTD. : Form 8.3 - Shire Plc
DJ
02:02pSHIRE PLC SHIRE PLC : Statement Re Revised -2-
DJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:38aPremarket analyst action - healthcare 
02:48aIf Takeda Walks Then Shire Could Crater 
04/23SYNERGY PHARMACEUTICALS : Best Drug + Terrible Management = Terrible Investment 
04/23Unity Biotechnology Finalizes $85 Million IPO Terms 
04/23BIOTECH FORUM : The Week Ahead 
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
Latest Tweets
01:29pUPDATE: Citi Resumes Allergen $AGN at Buy  
12:17pCiti Resumes Allergen $AGN at Buy  
08:48a$AGN $SHPG $TKPYY  
07:57aAllergan $AGN Given a $215.00 Price Target by Credit Suisse Group Analysts  
04:51a? Recap | Allergan moves in as Shire rebuffs $63 billion Takeda bid: sources .. 
More tweets
Qtime:228
Financials ($)
Sales 2018 15 225 M
EBIT 2018 7 285 M
Net income 2018 -908 M
Debt 2018 23 926 M
Yield 2018 1,82%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,17x
EV / Sales 2019 4,83x
Capitalization 54 802 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 208 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-3.10%54 802
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%192 109
MERCK AND COMPANY7.07%158 571